Exploiting pyocyanin to treat mitochondrial disease due to respiratory complex III dysfunction

被引:0
作者
Roberta Peruzzo
Samantha Corrà
Roberto Costa
Michele Brischigliaro
Tatiana Varanita
Lucia Biasutto
Chiara Rampazzo
Daniele Ghezzi
Luigi Leanza
Mario Zoratti
Massimo Zeviani
Cristiano De Pittà
Carlo Viscomi
Rodolfo Costa
Ildikò Szabò
机构
[1] University of Padova,Department of Biology
[2] CNR Institute of Neuroscience,Department of Biomedical Sciences
[3] University of Padova,Unit of Medical Genetics and Neurogenetics
[4] Fondazione IRCCS Istituto Neurologico Carlo Besta,Department of Pathophysiology and Transplantation
[5] University of Milan,Department of Neurosciences
[6] University of Padova,Department of Molecular and Cell Biology
[7] Venetian Institute of Molecular Medicine,undefined
[8] University of California,undefined
来源
Nature Communications | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Mitochondrial diseases impair oxidative phosphorylation and ATP production, while effective treatment is still lacking. Defective complex III is associated with a highly variable clinical spectrum. We show that pyocyanin, a bacterial redox cycler, can replace the redox functions of complex III, acting as an electron shunt. Sub-μM pyocyanin was harmless, restored respiration and increased ATP production in fibroblasts from five patients harboring pathogenic mutations in TTC19, BCS1L or LYRM7, involved in assembly/stabilization of complex III. Pyocyanin normalized the mitochondrial membrane potential, and mildly increased ROS production and biogenesis. These in vitro effects were confirmed in both DrosophilaTTC19KO and in Danio rerioTTC19KD, as administration of low concentrations of pyocyanin significantly ameliorated movement proficiency. Importantly, daily administration of pyocyanin for two months was not toxic in control mice. Our results point to utilization of redox cyclers for therapy of complex III disorders.
引用
收藏
相关论文
共 106 条
  • [1] Ghezzi D(2018)Human diseases associated with defects in assembly of OXPHOS complexes Essays Biochem. 62 271-286
  • [2] Zeviani M(2009)Assembly of the oxidative phosphorylation system in humans: what we have learned by studying its defects Biochim. Biophys. Acta 1793 200-211
  • [3] Fernandez-Vizarra E(2006)Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders Cell Metab. 3 9-13
  • [4] Tiranti V(2019)Mitohormesis and metabolic health: the interplay between ROS, cAMP and sirtuins Free Radic. Biol. Med. 141 483-491
  • [5] Zeviani M(2015)Nuclear gene mutations as the cause of mitochondrial complex III deficiency Front. Genet. 6 134-185
  • [6] Smeitink JA(2009)Respiratory-chain diseases related to complex III deficiency Biochim. Biophys. Acta 1793 181-130
  • [7] Zeviani M(1999)A nonsense mutation (G15059A) in the cytochrome b gene in a patient with exercise intolerance and myoglobinuria Ann. Neurol. 45 127-1044
  • [8] Turnbull DM(1999)Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA N. Engl. J. Med. 341 1037-133
  • [9] Jacobs HT(1999)A 4-base pair deletion in the mitochondrial cytochrome b gene associated with parkinsonism/MELAS overlap syndrome Ann. Neurol. 45 130-1410
  • [10] Palmeira CM(2000)Mitochondrial encephalomyopathy and complex III deficiency associated with a stop-codon mutation in the cytochrome b gene Am. J. Hum. Genet. 67 1400-263